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Allogeneic hematopoietic stem cell transplantation is a curative treatment for numerous 
hematological malignancies. However, acute graft-versus-host disease (aGvHD) is a major 
complication affecting 40–70% of all transplant patients, whereby the earliest and most 
frequent presentation is in the skin. MicroRNAs play a role in varied biological process and 
have been reported as potential biomarkers for aGvHD. More recently, microRNAs have 
received added attention as circulatory biomarkers that can be detected in biofluids. In 
this study, we performed global microRNA expression profiling using a discovery cohort of 
diagnostic cutaneous aGvHD biopsies (n = 5, stages 1–3) and healthy volunteers (n = 4), in 
order to identify a signature list of microRNAs that could be used as diagnostic biomarkers 
for cutaneous aGvHD. Candidate microRNAs (n = 8) were then further investigated in a 
validation cohort of post-HSCT skin biopsies (n = 17), pre-HSCT skin biopsies (n = 6) and 
normal controls (n = 6) for their association with aGvHD. Expression of let-7c (p = 0.014), 
miR-503-5p (p = 0.003), miR-365a-3p (p = 0.02), miR-34a-5p (p < 0.001) and miR-34a-3p 
(p =  0.006) were significantly differentially expressed between groups and significantly 
associated with survival outcome in post-HSCT patients (miR-503-5p ROC AUC = 0.83 
p = 0.021, Log Rank p = 0.003; miR-34a-3p ROC AUC = 0.93, p = 0.003, Log Rank 
p = 0.004). There was no association with relapse. A statistical interaction between miR-
34a-3p and miR-503-5p (p = 0.016) was diagnostic for aGvHD. Expression levels of the 
miR-34a-5p protein target p53 were assessed in the epidermis of the skin, and an inverse 
correlation was identified (r2 = 0.44, p = 0.039). Expression of the validated candidate 
microRNAs was also assessed at day 28 post-HSCT in the sera of transplant recipients, 
in order to investigate their potential as circulatory microRNA biomarkers. Expression 
of miR-503-5p (p = 0.001), miR-34a-5p (p = 0.005), and miR-34a-3p (p = 0.004) was 
significantly elevated in the sera of patients who developed aGvHD versus no-aGvHD 
(n = 30) and miR-503-5p was associated with overall survival (OS) (ROC AUC = 0.80, 
p = 0.04, Log Rank p = 0.041). In conclusion, this investigation reports that microRNA 
expression levels in clinical skin biopsies, obtained at the time of cutaneous aGvHD onset, 
show potential as diagnostic biomarkers for aGvHD and as predictive biomarkers for OS. 
In addition, the same microRNAs can be detected in the circulation and show predictive 
association with post-HSCT outcomes.
Keywords: microrna, gvhD, biomarker, molecular profiling, cutaneous
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inTrODUcTiOn
Skin is the largest organ of the human body, and it is more fre-
quently affected by acute graft-versus-host disease (aGvHD) (1). 
Cutaneous aGvHD manifests as a sequence of events that can be 
divided into three phases. Phase I of cutaneous aGvHD involves the 
activation of resting Langerhans cells, due to the release of cytokines 
from damaged host tissues during the chemotherapy regimen and/
or irradiation therapy. Phase II of cutaneous aGvHD occurs post 
allogeneic hematopoietic stem cell transplantation (allo-HSCT) 
when donor T-cells recognize the antigens presented by activated 
host dendritic cells (DCs). During phase III, immature keratino-
cytes undergo apoptosis due to the “cytokine storm,” which 
exacerbates histological skin damage (2). Cutaneous aGvHD sever-
ity is determined by trained independent histopathologists (3).
Currently, biomarkers that can be reliably used in the clinic 
to stratify patients for improved treatment response, diagnose 
aGvHD, or predict patient survival outcome are absent. Recently, 
the roles of several microRNAs have been investigated in aGvHD. 
miR-146a has been shown to be downregulated in severe-aGvHD 
murine models, and its target Traf6 elevated, leading to activation 
of the NFκB pathway (4). Likewise, elevated levels of miR-155 
were expressed in the gut of severe-aGvHD patients when com-
pared with normal biopsies (5). miR-34a has been shown to be 
expressed at higher levels post-transplant in the gut of patients 
with aGvHD grades II–IV compared with patients with grades 
0–I (6). miR-100 expression was shown to be increased in the gut 
of mice without aGvHD, therefore suggesting a protective func-
tion (7). A predictive signature list of microRNAs (miR-423, miR-
199a-3p, miR-93*, and miR-377) for aGvHD has previously been 
detected and validated in the plasma/sera of allo-HSCT patients 
(8, 9). These microRNAs were able to discriminate patients who 
had developed aGvHD from those who had not (non-aGvHD 
group). The microRNAs were associated with reduced overall 
survival (OS) and aGvHD severity (8). Circulatory microRNAs 
have also been globally profiled in the context of aGvHD (10) 
and tissue-specific microRNA expression patterns have been 
examined in a rat model of aGvHD (11). Circulatory microRNAs 
show great promise as potential biomarkers, due to the ease and 
non-invasive nature of sample collection.
In this study, in the discovery cohort, skin biopsies were col-
lected from normal controls, as well as pre-transplant and 
post-transplant patients at the time of aGvHD disease onset. The 
samples were analyzed to determine the diagnostic potential of 
microRNAs in cutaneous aGvHD and their prognostic potential 
for predicting patient survival. Global microRNA profiling using 
RT-qPCR was performed to identify a signature microRNA list, 
which was then further validated in a larger patient validation 
cohort. Expression of miR-503-5p, miR-34a-5p, miR-34a-3p, and 
let-7c-5p was associated with aGvHD incidence and survival. 
Results showed that miR-34a-5p was the most promising micro-
RNA for determining aGvHD severity, based on its significant 
differential expression levels across all the comparative groups. 
The protein targets (p53 and c-Myc) of miR-34a-5p were inves-
tigated by immunohistochemistry and showed association with 
expression of miR-34a-5p and skin aGvHD stage. Studies have 
shown the existence of a positive feedback loop between p53 and 
miR-34a (12). Likewise, c-Myc expression is suppressed by miR-
34a (13). Interestingly, c-Myc has numerous functions in hema-
topoiesis such as regulating hematopoietic stem cell regeneration 
and differentiation (14). c-Myc protein is a transcription factor 
that is constitutively expressed in many tumors and impacts 
microRNA biogenesis steps in the nucleus (15). Moreover, c-Myc, 
p53, and miR-34a are all involved in the p53 pathway and the 
epithelial–mesenchymal transition network (16). In the context 
of allo-HSCT, p53-deficient mice that develop aGvHD have a 
better OS when compared with mice with at least one copy of the 
gene (17). Finally, analysis of the expression of candidate micro-
RNAs was assessed in non-invasive serum samples, in order to 
evaluate their circulatory biomarker capacity. This would be of 
great potential clinical benefit, as biofluid samples are preferable 
to using invasive diagnostic skin biopsies.
Overall, the aims of this investigation were (1) to identify a list 
of microRNAs with significant potential to diagnose cutaneous 
aGvHD and to explore their impact on their predicted protein 
targets, (2) to predict OS and risk of relapse, (3) to further explore 
the circulatory biomarker potential of candidate microRNAs.
MaTerials anD MeThODs
Patient criteria
Research was granted ethical approval by the Newcastle and North 
Tyneside Research Ethics Committee (REC Ref: 14/NE/1136 and 
07/H0906/131). Participants gave full informed written consent 
for their samples to be used for research purposes. Skin bio psies 
were obtained from allo-HSCT patients pre- (n = 6) and post-
transplantation (n = 17) as well as from healthy volunteers (n = 6) 
with informed written consent. Skin histopathological aGvHD 
stage was evaluated by two independent histopathologists who 
were blinded to the origin of the sample, using the Glucksburg 
(3) criteria. All skin biopsies were collected pre-transplantation 
and at the time of aGvHD onset. Blood samples were collected 
from HSCT patients (n = 30) at day 28 (D28) post-HSCT in 7-ml 
vacutainers containing no anti-coagulant from patients undergo-
ing allo-HSCT (years 2009–2013). Clinical details of the cohorts 
are shown in Tables 1–3. To verify that differential microRNA 
expression levels were only due to either aGvHD or a result of 
transplantation, stringent criteria were set that excluded any 
patient who had received donor-lymphocyte infusion, had cyclo-
sporine withdrawal, had received steroids, or had developed late 
onset aGvHD (post-100 days from the date of transplantation). 
Thus, only patients with classic aGvHD (allo-HSCT to onset 
≤100 days) were included in all analyses.
Total rna extraction
Skin biopsies (1–4  mm) collected from patients and healthy 
volunteers were stored in RNA later buffer at −20°C until RNA 
extraction. Total RNA was extracted as per the manufacturer’s 
protocol from clinical skin biopsies using the mirVana microRNA 
Isolation kit (Life Technologies, USA). Blood samples were left to 
clot, the supernatant centrifuged at 500 × g for 5 min and stored at 
−80°C. Serum aliquots were centrifuged at 4,500 × g for 15 min 
to remove platelets before use. Total RNA was extracted using the 
Table 1 | Patient characteristics for the discovery cohort global microRNA skin 
profiling analysis.
Patient characteristics a1292 a2224 a2274 a1300 a2137
Diagnosis NHL MDM ALL CLL AML
Age 63 58 19 61 66
Transplant type MUD MUD SIB MUD MUD
Source PBSC PBSC PBSC PBSC PBSC
Protocol Flu Mel Flu Mel TBI Cy Flu Mel Flu Mel
Campath protocol (mg) 60 90 30 60 60
RIC Yes Yes No Yes Yes
Status at Tx CR1 CR1 CR1 CR CR2
CMV patient − + + + −
CMV donor − − + + +
Patient sex M M M M M
Donor sex M F F M M
Skin histopathological stage 2 3 2 1 1
Days from Tx (aGVHD onset) 23 18 79 76 33
Overall clinical aGVHD grade II IV II I II
Chronic GVHD N/A Yes Yes Yes Yes
Relapse No No No No No
Skin biopsies (n = 5) were taken from allo-HSCT patients. Exiqon miRCURY LNATM 
Universal Reverse Transcription microRNA Human Panel I and II were used for the 
global profiling analysis.
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CLL, chronic 
lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma; ALL, acute lymphocytic 
leukemia; SIB, sibling transplant; MUD, matched unrelated donor; PBSC, peripheral 
blood stem cells; Flu, fludarabine; Mel, melphalan; Alem, alemtuzumab; Tx, transplant; 
RIC, reduced intensity conditioning; CR1, complete remission 1; CR2, complete 
remission 2; CR, complete remission; CMV, cytomegalovirus; M, male; F, female; 
+, positive; −, negative, chronic GVHD N/A, not applicable as patient died before 
assessment; allo-HSCT, allogeneic hematopoietic stem cell transplantation.
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NORGEN BioTek® Total RNA Purification Kit, from 250  µl of 
serum. Extraction was performed in accordance with supplier’s 
guidelines, with lysis Buffer RL mixed with β-mercaptoethanol 
100:1 throughout. The RNA was eluted in 50 µl of elution-solution 
A and immediately stored at −80°C.
Quantitative rT-Pcr
Global microRNA profiling in the skin samples was performed 
by The Exiqon MicroRNA qPCR Service. Following three initial 
quality control checks to assess RNA integrity, purity, and detect 
PCR inhibitors, 40 ng of total RNA was reverse transcribed to 
cDNA as per the miRCURY LNA™ Universal RT microRNA 
PCR protocol. Each cDNA was diluted 100× and then run on 
both Human panel I (372 microRNAs) and Human panel  II 
(367 microRNAs), equating to n  =  739 microRNAs, n  =  3 
inter-plate calibrators, n = 6 reference controls and one control 
set (RNA spike-in). None of the samples were pre-amplified. 
This was followed by the qPCR step which was performed on 
a Roche LightCycler 480. A total of 186/739 microRNAs (25%) 
were detectable in all the samples in this cohort. For statistical 
calculations, 245 microRNAs with expression levels of Cq < 35 
detected in at least three skin biopsies per group were included. 
The mean of the 186 detected microRNAs (with Cq < 31) was 
used to normalize individual assay expression. For the valida-
tion study, universal cDNAs were synthesized using locked 
nucleic acid primers and universal cDNA master mix (Exiqon, 
Denmark; Product No: 203301) as per the manufacturer’s 
protocol. Thermal cycler (Applied Biosystems, 2720 Thermal 
Cycler) conditions comprised of 42°C for 60  min, 95°C for 
5  min, and then samples were stored at −4°C until use. The 
RT-PCR reaction step consisted of microRNA-specific forward 
and reverse primers (see Table S1 in Supplementary Material) 
to amplify individual microRNA of interest. ExiLENT SYBR® 
Green (Product No: 203402) was used for the detection of 
amplified microRNA products, which was followed by melting 
curve analysis upon standard qPCR completion as per the manu-
facturer’s protocol. Normfinder was used to determine the most 
suitable microRNA for normalization of the validation data (18). 
miR-103-3p and SNORD48 were used as endogenous controls, 
with analysis based on the geometric mean for normalization of 
the expression results.
For serum samples, microRNA-specific cDNA was gener-
ated using the TaqMan® MicroRNA Reverse Transcription Kit 
(Applied Biosystems®) and TaqMan® MicroRNA Assays (Applied 
Biosystems®), according to the supplier’s instructions. Each 
reverse transcription contained 5  µl of total RNA and heating 
was performed according to supplier recommended cycling 
conditions. MicroRNA-specific qRT-PCR reactions comprised 
of TaqMan® MicroRNA Assays (Applied Biosystems®) and 
SensiFAST™ Probe Hi-Rox Reagent (Bioline). Each 10 µl reac-
tion was carried out in triplicate. MicroRNA expression was 
normalized to two previously identified endogenous controls 
(U6 and HY3) (19). Reactions were cycled using the 7900 Real-
Time PCR System (Applied Biosystems®), using manufacturer’s 
recommended cycling conditions.
Detection of c-Myc and p53
Pre- (n =  5) and post- (n =  17) allo-HSCT skin biopsies were 
sectioned and stained for c-Myc (Abcam, Epitomics at 1:10 dilu-
tion) and p53 (Ventana, commercially supplied dilution) proteins 
using standard formalin-fixed paraffin-embedded immunohisto-
chemistry method (Histopathology Laboratory, Royal Victoria 
Infirmary, Newcastle upon Tyne).
Quickscore Method for assessment  
of immunohistopathological samples
The “quick score method” is a semi-quantitative method (20), used 
for assessing the percentage of positively stained cells for both 
p53 and c-Myc proteins. A consensus score was calculated as each 
section was assessed by two independent researchers, who were 
blinded to the origin of the samples. The score for each biopsy was 
calculated by considering both the intensity and the proportion of 
cells (see Table S2 in Supplementary Material) within that intensity 
[Quickscore formula =  (Intensity 0 × Proportion) +  (Intensity 
1  ×  Proportion)  +  (Intensity 2  ×  Proportion)  +  (Intensity 
3 × Proportion)]. The whole section was used for calculating the 
percentage positivity scores. Since miR-34a expression was quan-
tified in both the epidermis and dermis, quick scores were calcu-
lated (1) for the entire section regardless of the skin layer and (2) in 
each skin layer individually.
statistical analysis
Unsupervised hierarchical clustering analysis was performed 
using RStudio™ Version 0.98.501 (RStudio, Inc., USA). The global 
profiling results were analyzed using one-way ANOVA on SPSS 
Table 2 | Patient characteristics for the skin validation cohort.
cohort characteristics skin validation cohort
histopathological stage ( n = 17)
0–1 (n = 10) 2–3 ( n = 7) Difference ( p-value)
no. % no. %
Patient age (median years) 47 (19–65)
Patient sex Female 2 67 1 33 1.000
Male 8 57 6 43
Donor sex Female 3 60 2 40 1.000
Male 7 58 5 42
Graft source BM 1 100 0 0 1.000
PBSC 9 56 7 44
Underlying disease ALL 1 50 1 50 0.907
AML 1 33 2 67
MDS 3 75 1 25
MF 0 0 1 100
NHL 3 60 2 40
CLL 1 100 0 0
MM 1 100 0 0
Regimen Myeloablative 1 33 2 67 0.537
RIC 9 64 5 36
Protocol Cy TBI Alem 1 33 2 67 0.481
Flu Bus Alem 1 33 2 67
Flu Mel Alem 8 73 3 27
Campath 30 mg 3 60 2 40 1.000
60 mg 6 60 4 40
90 mg 1 50 1 50
Relationship SIB 2 50 2 50 1.000
MUD 8 62 5 38
Patient CMV status Negative 4 57 3 43 1.000
Positive 6 60 4 40
Donor CMV status Negative 6 60 4 40 1.000
Positive 4 57 3 43
HLA class I compatibility None 8 67 4 33 0.593
One 2 40 3 60
HLA class II compatibility None 3 50 3 50 0.219
One 3 43 4 57
Two 4 100 0 0
Survival status Alive 7 78 2 22 0.153
Deceased 3 38 5 62
Relapse status No 6 55 5 45 1.000
Yes 4 67 2 33
Disease status at transplant CR 1 100 0 0 0.586
CR1 4 50 4 50
CR2 4 80 1 20
PR 1 33 2 67
Histopathological aGvHD stage was used for patient groupings. Fisher’s exact test was used to estimate the difference in frequencies between the aGvHD groups.
BM, bone marrow; PBSC, peripheral blood stem cells; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; 
NHL, non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; RIC, reduced intensity conditioning; Cy, cytarabine; TBI, total body irradiation; Alem, 
alemtuzumab; Flu, Fludarabine; Bus, Busulfan; Mel, Melphalan; SIB, Sibling; MUD, Matched unrelated donor; CMV, Cytomegalovirus; CR (1-2), Complete remission;  
PR, Progression.
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version 21 (IBM, SPSS Inc., USA). Quantitative RT-PCR results 
were processed using SDS 2.4 (Life Technologies, USA, v2.4). 
Differential expression of microRNAs in skin biopsies between 
all groups (controls, pre-transplant, grades 0–I, and grades 
II–III/IV) was determined using Kruskal–Wallis one-way 
analysis of variance with Dunn’s post  hoc test on GraphPad 
Prism 5 (GraphPad Software, Inc., USA). Significance was set at 
p < 0.05. Differential expression of microRNAs in serum samples 
between two groups was assessed using Mann–Whitney U test on 
GraphPad Prism 5. To determine trends in the expression levels for 
Table 3 | Patient characteristics for the serum cohort.
cohort characteristics serum cohort
Overall agvhD grade ( n = 30)
0 (n = 13) i–iii (n = 17) Difference ( p-value)
no. % no. %
Patient age (median years) 50 (23–66)
Patient sex Female 3 33 6 67 0.691
Male 10 48 11 52
Donor sex Female 4 44 5 56 1.000
Male 9 43 12 57
Graft source BM 0 0 1 100 1.000
PBSC 13 45 16 55
Underlying disease ALL 1 50 1 50 0.985
AML 3 37 5 63
MDS 3 43 4 57
HD 1 50 1 50
NHL 3 33 6 67
CLL 2 100 0 0
Regimen Myeloablative 0 0 3 100 0.238
RIC 13 48 14 52
Protocol Cy TBI Alem 0 0 1 100 0.677
Flu Bus Alem 2 50 2 50
Flu Mel Alem 10 50 10 50
Other 1 25 4 75
Campath 30 mg NK NK NK NK NK
60 mg NK NK NK NK
90 mg NK NK NK NK
Relationship SIB 3 43 4 57 1.000
MUD 10 43 13 57
Patient CMV status Negative 8 44 10 56 1.000
Positive 5 63 7 27
Donor CMV status Negative 10 48 11 52 0.691
Positive 3 33 6 67
HLA class I compatibility None NK NK NK NK NK
One NK NK NK NK
HLA class II compatibility None NK NK NK NK NK
One NK NK NK NK
Two NK NK NK NK
Survival status Alive 6 38 10 62 0.713
Deceased 7 50 7 50
Relapse status No 4 25 12 75 0.064
Yes 9 50 5 50
Disease status at transplant CR 2 40 3 60 0.847
CR1 5 56 4 44
CR2 4 36 7 64
PR 2 40 3 60
Overall clinical aGvHD grade was used for patient groupings. Fisher’s exact test was used to estimate the difference in frequencies between the aGvHD groups.
BM, Bone marrow; PBSC, Peripheral blood stem cells; ALL, Acute lymphocytic leukemia; AML, Acute myeloid leukemia; MDS, Myelodysplastic syndrome; HD, Hodgkins 
disease; NHL, Non-Hodgkin’s lymphoma; CLL, Chronic lymphocytic leukemia; RIC, Reduced intensity conditioning; Cy, Cytarabine; TBI, Total body irradiation; Alem, 
Alemtuzumab; Flu, Fludarabine; Bus, Busulfan; Mel, Melphalan; SIB, Sibling; MUD, Matched unrelated donor; CMV, Cytomegalovirus, CR (1-2), Complete remission; PR, 
Progression; NK, not known.
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aGvHD severity, the Jonckheere–Terpstra test (SPSS version 21) 
was also performed for the microRNAs in the signature list. 
Generalized linear models (ordinal logistic regression) (GLMs) 
were performed to find the significance and statistical interac-
tions between microRNAs in the signature list using SPSS version 
21 (IBM, SPSS Inc., USA). The main effect is statistically defined 
as an effect of an independent variable on the outcome, while an 
interaction is a measure of two or more independent variables 
on the dependent outcome (21). In this scenario, the main effect 
was the effect of the individual miRNA expressions or significant 
6Atarod et al. MicroRNA Expression in Cutaneous GvHD
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clinical risk factors on aGvHD outcome and the interaction was 
a measure of the effect of one independent miRNA expression 
level as it differed at every condition in comparison to the other 
independent miRNA expression levels (21). In order to predict 
aGvHD outcome from a list of covariates, GLMs were built using 
the binary and/or ordinal logistic regressions. The equation for 
the binary or ordinal regression models that was used for deter-
mining aGvHD grade (outcome) was aGvHD grade (cumulative 
logit function) = β0 + β1 (miRNA expression 1) + β2 (miRNA 
expression 2) + β3 (miRNA expression 1 × miRNA expression 2). 
β0 =  intercept coefficient and β1–3 =  the coefficient of each 
miRNA expression. Rotational 3D scatterplots were generated 
using JMP® Version 11 (SAS Institute Inc., Cary, NC, USA, 1989–
2007). Variable screening for both clinical risk factors (patient 
age, donor–patient relationship, patient and donor gender, CMV 
status, graft source, underlying disease, mismatches in HLA Class 
I, and skin histopathological aGvHD grade) and microRNAs was 
performed using univariate Cox regression analyses. Variables 
considered as associated with outcome (p < 0.2) were entered as 
candidates in a stepwise multivariate analysis. Receiver operat-
ing characteristic (ROC) analysis was performed using survival 
status as the binary state (classification) variable and microRNA 
expression on a continuous scale as the test variable, to deter-
mine area under the curve (AUC) (SigmaPlot v12.5). OS was 
calculated using the time in months from transplant to death 
or last follow-up (October 2014). Survival plots were generated 
using the Kaplan–Meier (K.M) method and differences in out-
come were assessed for significance using the Log-Rank (L.R) 
test (SPSS v21). The threshold to determine dichotomies for 
microRNA expression (low and high expression) was evaluated 
by ROC analysis.
resUlTs
Discovery cohort: Distinct Microrna 
expression clusters Differentiate between 
Post allo-hscT and control skin biopsies
The characteristics of the discovery transplant patient cohort 
(n =  5) for which skin biopsies were profiled are provided in 
Table 1. The group comprised of male patients with heterogene-
ous underlying diseases and median age 61 years (range: 19–66) 
who had undergone allo-HSCT between 2010 and 2012. All the 
patients received peripheral blood stem cells (PBSC) as the graft. 
Four patients had reduced conditioning regimens (Fludarabine 
and Melphalan), while one had myeloablative treatment (total 
body irradiation and cyclophosphamide). All five patients were in 
complete remission at the time of transplantation. Overall clinical 
aGvHD (grades I–IV) developed with a median onset of 33 days 
(range: 18–79). All patients had matched unrelated donor trans-
plants, except for the youngest patient (19 years old), who had 
a sibling donor and myeloablative conditioning. Four patients 
developed chronic GvHD (cGvHD) >100 days after transplanta-
tion, and one patient had died before cGvHD assessment. None 
of the patients relapsed. This heterogeneity was representative of 
the allo-HSCT clinic. Four healthy volunteers were included in 
this discovery cohort.
In the discovery cohort, skin samples with similar microRNA 
expression values were grouped by performing unsupervised 
hierarchical clustering. Only microRNAs that were expressed 
in all skin biopsies, including the healthy control biopsies 
(n  =  186), were included in the final analysis. MicroRNA 
expression in the skin biopsies was used to create a dendrogram 
and heatmap (Figure  1). The microRNA expression profiles 
showed considerable patient-to-patient variation, as depicted 
by the height of the branches, but the most pronounced parti-
tion on the dendrogram led to segregation of the skin biopsies 
into two distinct clusters: the healthy control group in one 
branch and the allo-HSCT group in the other (Figure 1). The 
heatmap showed three distinct expression regions, whereby 
highly upregulated microRNAs clustered in the top branch, and 
the downregulated microRNAs clustered in the lower section 
of the heat map. miR-720 was highly expressed in all nine skin 
biopsies (Mean ΔCp = 9.10) (Figure 1) and has been reported 
to be an important regulator of T cell proliferation (22). miR-
34a-5p expression was significantly different in the healthy 
controls compared with the allo-HSCT group [control mean 
ΔCp = 1.97 (range = 1.74–2.25), allo-HSCT mean ΔCp = 3.30 
(range = 2.57–4.07); p < 0.001] (Figure 1). miR-451-5p is highly 
expressed in erythrocytes (23) and its levels were highly vari-
able in all the skin biopsies (range = −1.33 to 4.90, SD = 2.28) 
(Figure  1). This could be attributed to the differences in the 
vascular network present in each skin biopsy.
A supervised analysis was performed using the discovery 
cohort of skin biopsies to compare microRNA expression levels 
between healthy controls, skin aGvHD stages 0–1 (n =  2) and 
skin aGvHD stages 2–3 (n = 3). Eight microRNAs (miR-503-5p 
p < 0.001, miR-21-3p p < 0.001, miR-34a-5p p < 0.001, let-7c-5p 
p < 0.001, miR-142-3p p = 0.005, miR-365a-3p p < 0.001, miR-
23b-3p p = 0.001, and miR-24-3p p = 0.017) were selected for 
further validation by RT-qPCR, based on their differential expres-
sion levels between control and skin aGvHD groups (Figure S1 
in Supplementary Material).
Validation cohort: let-7c-5p, mir-503-5p, 
mir-365a-3p, mir-34a-5p, and mir-34a-
3p are Differentially expressed in Post 
allo-hscT skin biopsies
For the validation study, skin biopsies were taken from transplant 
patients pre-HSCT (n = 6) and post-HSCT (n = 17). Characteristics 
of the post-HSCT patients are shown in Table  2. The cohort 
comprised of 3 females and 14 males, with biopsy confirmed histo-
pathological skin aGvHD stage 0 n = 3, stage 1 n = 7, stage 2 n = 6, 
stage 3 n = 1, and stage 4 n = 0. The median age was 47 years (range: 
19–65). Only one patient had a bone marrow infusion, while the 
remainder (n = 16) received PBSC. Three patients had undergone 
total body irradiation. Median overall clinical aGvHD onset (grade 0 
n = 1, grade I = 5, grade II = 8, grade III n = 1, grade IV n = 1) was 
23 days (range: 13–98) post allo-HSCT. In all, n = 5 (29.4%) of the 
patients had relapsed and n = 8 (47.1%) had died post allo-HSCT 
at the time of last follow-up. Pre-HSCT skin biopsies (n = 6) were 
taken from patients 7 days prior to transplantation and before the 
initiation of the conditioning regimen. The patients consisted of 3 
FigUre 1 | Continued
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FigUre 2 | Let-7c-5p, miR-503-5p, miR-365a-3p, miR-34a-5p and miR-34a-3p expression in the validation cohort skin biopsies. MicroRNA expression results for 
(a,F) let-7c-5p, (b,g) miR-503-5p, (c,h) miR-365a-3p, (D,i) miR-34a-5p and (e,J) miR-34a-3p were analysed on the basis of (a–e) histopathological skin aGvHD 
stage (0–3, n = 17) and (F–J) the overall aGvHD clinical grade (0–IV, n = 16). Kruskal-Wallis analysis of variance was used to determine the significance, set at 
p ≤ 0.05 (*). Scatterplots show the mean and SEM. Abbreviations: Normal, healthy controls; Pre-Tx, Pre-transplant.
FigUre 1 | Heat map showing skin biopsy discovery cohort global microRNA expression levels. Each row is representative of one microRNA and each column 
represents one sample. Unsupervised hierarchical clustering analysis was performed using the expression levels from n = 186 detectable microRNAs in the total 
discovery cohort (n = 9). The heatmap shows the top 50 microRNAs that were expressed in all 9 samples. The vertical dendrogram indicates three distinct 
microRNA clusters, based on the expression values in all samples. The scale of the dendrogram shows the distance, representing similarity between clusters.  
The horizontal dendrogram shows the clustering of samples into two clusters. Normalized log2 values were used for this analysis. The average linkage method  
was used for the unsupervised hierarchical clustering of the normalized expression results. Fold change range is from −5 to 10. Red boxes highlight microRNAs  
of interest. Over expressed = green cells, intermediate = light purple cells, under-expressed = dark purple cells. Post allo-HSCT samples are also labeled with their 
histopathological skin aGvHD stage (1–3) and overall clinical aGvHD grade (II–IV). Abbreviations: N, normal healthy control; allo-HSCT, allogeneic hematopoietic 
stem cell transplantation; aGVHD, acute graft-versus-host disease.
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females and 3 males of median age 46 years (range: 28–65) of het-
erogeneous underlying disease [Hodgkin’s disease (n = 1), chronic 
lymphocytic leukemia (n = 1), non-Hodgkin’s lymphoma (n = 1), 
acute myeloid leukemia (n =  1), and myelodysplastic syndrome 
(n = 2)].
In the validation cohort, RT-qPCR results confirmed that five 
of the eight target microRNAs identified in the discovery cohort 
were significantly differentially expressed across the four groups 
analyzed [pre-transplant (n = 6), healthy control (n = 6), grades 
0–I aGvHD (n = 10), and grades II–III aGvHD (n = 7)], accord-
ing to histopathological skin aGvHD stage [let-7c-5p (p = 0.014), 
miR-503-5p (p = 0.003), miR-365a-3p (p = 0.02), miR-34a-5p 
(p < 0.001), and miR-34a-3p (p = 0.006)] (Figures 2A–E) and 
overall aGvHD clinical grade [let-7c-5p (p = 0.005), miR-503-5p 
(p =  0.02), miR-365a-3p (p =  0.01), miR-34a-5p (p <  0.001), 
and miR-34a-3p (p  =  0.003)] (Figures  2F–J). miR-142-3p, 
miR-21-3p, miR-24-3p, and miR-23b-3p did not retain their 
significance (p < 0.05). Focusing on the histopathological skin 
aGvHD stage, there was a significant down-regulation of let-
7c-5p expression in the pre-transplant biopsies in comparison 
to the healthy controls (p  =  0.04) (Figure  2A). miR-503-5p 
expression was upregulated in skin biopsies taken from patients 
with skin aGvHD stages 2–3 in comparison to the pre-transplant 
group (p = 0.032) (Figure 2B). miR-365a-3p expression levels 
were downregulated in biopsies taken from patients with stages 
0–1 skin aGvHD compared with the pre-transplant (Tx) cohort 
(Figure  2C). miR-34a-5p expression levels were significantly 
up-regulated post-allo-HSCT, regardless of skin aGvHD stage 
(pre-Tx versus 0–1 p =  0.004, pre-Tx versus 2–3 p =  0.002) 
(Figure 2D). In addition, the expression of miR-34a-5p and miR-
34a-3p was significantly positively correlated in skin biopsies in 
this cohort (rs = 0.50, p = 0.006) (Figure S2 in Supplementary 
Material).
lower cutaneous mir-503-5p and  
mir-34a-3p expression is associated  
With improved Os
Receiver operating characteristic analysis of the validation 
cohort, based on individual microRNA expression, showed that 
miR-503-5p and miR-34a-3p predicted for OS (miR-503-5p 
AUC =  0.83, p =  0.021, miR-34a-3p AUC =  0.93, p =  0.003) 
(Figures 3A,B). MicroRNA expression was dichotomized (low 
or high expression), based on the optimal thresholds evalu-
ated by ROC analysis. The K.M method was used to generate 
survival plots. Low expression of miR-503-5p and miR-34a-3p 
FigUre 3 | Continued
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FigUre 3 | Association between cutaneous miR-503-5p and miR-34a-3p expression with overall survival (OS) and skin acute graft-versus-host disease  
(aGVHD) severity in the validation cohort. (a–D) Expression of miR-503-5p and miR-34a-3p in the skin validation cohort (n = 17) was analyzed according to OS. 
(a,b) miR-503-5p and miR-34a-3p expression was associated with OS according to receiver operator characteristic (ROC) analysis. ROC curves detailing area 
under the curve (AUC) and p-value significance are shown. (c,D) miR-503-5p and miR-34a-3p expression was dichotomized (low or high expression), based on  
the optimal thresholds evaluated by ROC analysis. Kaplan–Meier survival curves for OS were then generated, based on dichotomized microRNA expression. 
p-Values were calculated using the Log-Rank test. For both microRNAs, high expression was significantly associated with poor OS. (e) In patients with high levels  
of miR-34a-3p, miR-503-5p expression was associated with skin histopathological aGvHD. (F) However, in patients with low levels of miR-34a-3p, there was no 
association between miR-503-5p expression and skin aGvHD severity. (e,F) Histopathological grades are shown on the y-axis. The x-axis denotes microRNA 
expression. miR-503-5p expression levels were dichotomized based on miR-34a-3p expression.
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was significantly associated with longer OS [miR-503-5p 17.1 
versus 7.4 months median survival, L.R p = 0.003, hazard ratio 
(HR) = 7.7 (p = 0.014) and miR-34a-3p 12.0 versus 9.1 months 
median survival, L.R p  =  0.004, HR  =  10.93 (p  =  0.03)] 
(Figures 3C,D).
To obtain a set of predictors in a multivariate model for OS, 
variable selection was performed using both the clinical risk fac-
tors and microRNAs. From the preliminary univariate variable 
selection (which included patient age, donor-patient relationship, 
patient gender, CMV status, graft regimen, skin aGvHD stage, 
mismatches in HLA Class I, and underlying disease), clinical risk 
factors with p < 0.2 (24) were chosen as candidates in a “Forward 
Likelihood Ratio” stepwise Cox regression procedure alongside 
the microRNAs [i.e., patient CMV status (p = 0.146), mismatches 
in HLA Class I (p  =  0.187), skin histopathological aGvHD 
stage (p  =  0.115), miR-503-5p (p  =  0.014), and miR-34a-3p 
(p =  0.026) expression] (Table S3 in Supplementary Material). 
After variable selection, miR-503-5p [p = 0.020, HR = 6.87 (95% 
CI: 1.35–34.89)] was identified as an independent factor in the 
Cox regression equation.
statistical interaction between cutaneous 
mir-503-5p and mir-34a-3p is associated 
With skin agvhD stage
Statistical interactions between all microRNAs were also assessed 
in the validation cohort. Ordinal logistic regression analysis of 
skin histopathological aGvHD stage was performed incorpo-
rating both the main effect and interaction of all the validated 
microRNAs in a stepwise manner. Results showed that there was a 
statistically significant interaction between miR-503-5p and miR-
34a-3p expression (p = 0.016), with miR-503-5p having the most 
significant effect (p = 0.011) and miR-34a-3p as the moderator 
(p =  0.020) in this interaction. Clinical covariates (as for the 
survival analysis) were considered in the stepwise procedure, but 
none were significant in the final model.
A conditional relationship was also identified between miR-
503-5p and miR-34a-3p, such that when high levels of miR-34a-3p 
were expressed, higher levels of miR-503-5p were more clearly 
associated with severity of skin histopathological aGvHD stage 
(Figure 3E). However, the relationship between miR-503-5p and 
skin histopathological aGvHD severity was less apparent when 
levels of miR-34a-3p expression were low (Figure 3F). This find-
ing requires further investigation to elucidate whether a clinical 
or biological factor was the reason for this trend. To further 
understand the conditional interaction between miR-503-5p and 
miR-34a-3p, rotational 3D scatterplots were generated (Figure S3 
in Supplementary Material). Since miR-503-5p and miR-34a-3p 
were significantly associated with OS, non-parametric density 
contours based on the patient survival status were included, 
to aid visualization. The plots demonstrated the interaction 
between miR-503-5p and miR-34a-3p expression. None of the 
other microRNAs were associated with skin aGvHD stage, OS, 
or relapse.
c-Myc and p53-Positive cells  
are Present in cutaneous biopsies  
of allo-hscT Patients
Immunohistochemical analysis was performed to test whether 
c-Myc and p53 proteins, both of which are miR-34a-5p targets, 
were expressed in cutaneous biopsies from allo-HSCT patients 
pre- and post-transplantation. The majority of the activated 
c-Myc-positive cells, particularly those with high c-Myc intensity, 
were present in the basement membrane of skin histopathological 
stage 0 and stage 1 aGvHD biopsies (n = 9) (Figure 4). In stage 2 
and stage 3 aGvHD biopsies (n = 7), the complete epidermis stained 
positive for c-Myc and very few negatively staining cells were pre-
sent. A limited number of cells demonstrated cytoplasmic-only 
staining for c-Myc, while the majority showed both cytoplasmic 
and nuclear staining.
Likewise, cells that positively stained for p53 protein (Figure 4) 
were also analyzed for differences between pre- and post- 
allo-HSCT skin biopsies. Visualization of the sections showed 
positive cytoplasmic-nuclear staining for p53 under all 
histopathological conditions (pre-transplantation to stage 3 
aGvHD). p53-positive cells were localized in the epidermis. 
In healthy volunteers, p53-positive cells are confined to the 
basement membrane (25). Only occasional cells in the dermis 
were p53-positive. The majority of p53-positive cells stained 
with strong to moderate intensity. The dermis had less than 4% 
p53-positive cells and was therefore considered as p53-negative. 
Thus, for p53, the quick score method was calculated based only 
on the epidermis.
p53 Positively correlates With mir- 
34a-5p expression in the epidermis
There was no statistically significant correlation between miR-
34a (-5p or -3p) expression levels and the proportion of c-Myc-
positive cells (rs = 0, p > 0.05). No association with the percentage 
of c-Myc-positive cells was identified, and this was confirmed by 
performing Jonckheere’s trend test (p = 0.988) (data not shown).
Interestingly, in all samples (n =  22), comprising both the 
validation cohort (n = 17) and pre-transplant biopsies (n = 5), 
FigUre 4 | Example skin biopsy positivity for c-Myc and p53 protein. (a) c-Myc-positive cells demonstrated variable expression intensities (low, moderate, and 
high). No skin acute graft-versus-host disease (aGvHD) biopsies had high intensity c-Myc-positive cells in the basement membrane, while in stages 2–3 skin aGvHD 
positivity for c-Myc was observed throughout the entire epidermis. Positive-c-Myc proteins were also present in the pre-transplant skin biopsies. (b) p53-positive 
cells were present in pre-transplant skin biopsies, but were limited in number. Strong positive staining was observed with skin aGvHD severity. (a,b) The first  
row shows the two pre-transplant skin sections that were taken from the individuals with cutaneous histopathological aGvHD stage 0 and stage 1 (second row), 
respectively. Stage 3 skin sections showed severe cutaneous aGvHD, with separation between the epidermis and dermis. For both c-Myc and p53, the number  
of cells that infiltrated the dermis gradually increased from no GVHD (stage 0) to severe skin aGvHD (stage 3). Breast carcinoma tissues were used as a negative  
and positive control for c-Myc and p53. The images were taken at 20× magnification using AxioCamMR3.
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miR-34a-5p expression alone positively correlated with the 
percentage of p53-positive cells in the epidermis (rs  =  0.44, 
p  =  0.039) (Figure S4 in Supplementary Material). In post-
allo-HSCT skin biopsies only (n = 17), there was no significant 
correlation between p53-positive cells and microRNA expres-
sion. There was a significant difference between the percentage 
p53-positive cells pre-transplantation and skin aGvHD stages 
2 and 3 (p =  0.045) (Figure S4 in Supplementary Material). 
Jonckheere’s trend test confirmed the significant trend toward 
higher p53-positive cells with increasing skin aGvHD stage post 
allo-HSCT (p = 0.009).
serum expression of mir-503-5p,  
mir-34a-3p, mir-34a-5p, and let-7c-5p  
is associated With agvhD incidence
In order to assess the predictive capacity of circulatory micro-
RNAs, expression of miR-503-5p, miR-34a-5p, miR-34a-3p, and 
let-7c-5p was further investigated at day 28 (D28) post-HSCT in 
transplant patient serum samples (n =  30) (Table 3). Analyses 
were based on both skin histopathological stage (mean onset 
49 days post-HSCT, stage 0 n = 13, stage 1 n = 10, stage 2 n = 4, 
stage 3 n =  3) and overall clinical aGvHD grade (mean onset 
54 days post-HSCT, grade 0 n = 13, grade I n = 9, grade II n = 5, 
grade III n = 3). Initial analysis indicated that expression of all 
microRNAs was higher in patients with both skin and overall 
clinical aGvHD, including milder stage/grade 1/I, compared with 
no-aGvHD (data not shown). Thus, patient groups were dichoto-
mized according to skin stage 0 versus 1–3 or overall grade 0 
versus I–III for subsequent analysis. miR-503-5p (p =  0.001), 
miR-34a-5p (p  =  0.005), and miR-34a-3p (p  =  0.004) were 
expressed at a higher level in patients at D28 post-HSCT who 
developed both skin and overall aGvHD (stages 1–3, grades I–III) 
(n = 17), compared with patients with no skin or overall aGvHD 
(n = 13) (Figure 5A).
When microRNAs were assessed in relation to individual 
skin aGvHD stage or clinical aGvHD grade, there was no 
significant difference in expression between disease stages or 
grades (p > 0.05, data not shown), indicating the microRNAs to 
be associated with skin and overall aGvHD incidence, but not 
severity (data not shown).
Following identification of differential expression of candi-
date microRNAs in patients who developed skin and overall 
aGvHD, ROC analysis was performed to identify time point-
specific microRNA prognostic ability. ROC analysis demon-
strated miR-503-5p (p = 0.01, AUC = 0.81), 34a-5p (p = 0.005, 
AUC = 0.83), and miR-34a-3p (p = 0.007, AUC = 0.82) to have 
prognostic ability at D28 with regard to aGvHD incidence 
(Figure 5B).
Correlation analysis was performed between all microRNAs, 
in both aGvHD and no-aGvHD patients. For aGvHD patients, 
correlation was detected between expression of miR-34a-5p and 
miR-34a-3p (r =  0.88, p <  0.0001) and, miR-34a-5p and miR-
503-5p (r =  0.51, p =  0.03), but not between miR-34a-3p and 
miR-503-5p (r = 0.35, p = 0.14). When assessing patients who 
did not develop aGvHD, no correlation was observed between 
expressions of any of the microRNAs (p > 0.05).
lower serum mir-503-5p expression  
is associated With improved Os
Cox regression analysis showed no significant relation between 
OS and miR-34a-5p (HR =  0.914, p =  0.61) nor miR-34a-3p 
(HR = 0.97, p = 0.86) serum expression at D28. Expression of 
miR-503-5p, however, showed a significant association with OS 
(HR = 6.86, p = 0.038).
miR-503-5p expression was dichotomized (low or high expres-
sion), based on the optimal thresholds evaluated by ROC analysis, 
and K.M plots were used to analyze cumulative survival. High 
miR-503-5p levels at D28 were significantly associated with poor 
OS (32.3 versus 54.9  months median survival, L.R p =  0.041) 
(Figure 5C). ROC analysis demonstrated miR-503-5p at day 28 
(p = 0.04, AUC = 0.80) to have prognostic ability with regard to 
OS (Figure 5D).
DiscUssiOn
The critical role of microRNA in disease pathology and devel-
opment has been highlighted in numerous studies to-date 
(26). MicroRNAs are cell-specific, stable, and therefore ideal 
biomarkers (27). Thus, this study aimed to identify a signature 
list of microRNAs that could discriminate mild (stage 1) from 
moderate to severe (stages 2 and 3) cutaneous aGvHD. Global 
microRNA profiling by RT-qPCR was carried out on normal and 
post-HSCT biopsies taken from patients with cutaneous aGvHD. 
Eight microRNAs that were differentially expressed across the 
groups (miR-142-3p, miR-34a-5p, miR-503-5p, let-7c-5p, miR-
21-3p, miR-365a-3p, miR-23b-3p, and miR-24-3p) were selected 
for individual validation by RT-qPCR in healthy controls and 
pre-transplant and post-transplant skin biopsies from patients 
with and without aGvHD. Four microRNAs (miR-34a-5p, miR-
34a-3p, let-7c-5p, and miR-503-5p) were further investigated in 
serum samples for their circulatory biomarker potential for skin 
and overall aGvHD.
Unsupervised hierarchical clustering of the global microRNA 
expression levels showed that there were two distinct clusters, 
supporting the hypothesis that healthy controls and allo-HSCT 
patients have different cutaneous microRNA expression patterns. 
The findings suggested that microRNAs could be deregulated as a 
result of both the allo-HSCT procedure and aGvHD disease onset. 
This is in agreement with previous studies that have reported 
differential expression of circulatory microRNAs post-cytotoxic 
therapy prior to HSCT, as well as in relation to aGvHD onset 
(10, 28). In the subsequent validation study, five microRNAs of the 
eight observed in the discovery cohort retained their significance 
(let-7c-5p, miR-503-5p, miR-365a-3p, and miR-34a-5p/-3p). 
Interestingly, only let-7c was significantly differentially expressed 
between normal controls and pre-HSCT patients (lower in pre-
HSCT), suggesting expression of this microRNA to be altered as 
a results of underlying disease. The results showed that let-7c-5p 
expression increased after transplantation, but it was surprising 
to find that levels in skin biopsies with skin aGvHD histopatho-
logical stages 2–3 were approximately the same as that of healthy 
controls. A previous study demonstrated that let-7c-5p is highly 
expressed in CD4+ T-cells in healthy individuals (29). Results in the 
FigUre 5 | Association between serum expression of miR-503-5p, miR-34a-5p and miR-34a-3p with skin histopathological aGvHD incidence, overall clinical 
aGvHD grade and overall survival. (a) Scatterplots demonstrating miR-503-5p, miR-34a-5p, and miR-34a-3p expression (mean and SEM) in serum samples at Day 
28 post-HSCT according to skin aGvHD stage/overall aGvHD grade. Significance was determined using the Student’s t-test. (b) Receiver operator characteristic 
(ROC) curves detailing area under the curve (AUC) and p-value significance for miR-503-5p, miR-34a-5p, and miR-34a-3p with incidence of skin aGvHD/clinical 
aGvHD. (c) Kaplan–Meier survival curves for OS, based on dichotomized miR-503-5p expression. p-Values were calculated using the Log-Rank test. (D) ROC 
curve detailing AUC and p-value significance for miR-503-5p and OS.
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healthy controls were, therefore, in concordance with this study. 
Swaminathan et al. (29) have shown that the expression of IL-10 
protein could be modulated by let-7c-5p. IL-10 is an anti-inflam-
matory cytokine that has been extensively studied in GvHD (30). 
At this stage, it could be postulated that let-7c-5p might play a role 
in immune-regulation rather than cutaneous aGvHD.
As the skin is involved in ~80% of GvHD cases, further under-
standing the repertoire of microRNA expression in a cutaneous 
aGvHD setting is important in order to better understand the 
complex nature of this disease. Although the data presented 
here strengthens the potential of miR-503-5p, miR-34a-5p, 
miR-34a-3p, and let-7c-5p for use as prospective cutaneous 
aGvHD biomarkers, the necessity for invasive biopsies is not 
advantageous. Therefore, studies were extended to assess their 
expression in serum samples pre- and post-transplant. Results 
showed that miR-503-5p, miR-34a-5p, and miR-34a-3p retained 
their biomarker potential with respect to skin and overall clinical 
aGvHD incidence, as demonstrated by high expression in aGvHD 
patients at D28 post-HSCT and subsequent ROC analysis.
When microRNA expression was assessed in relation to 
post-HSCT survival, lower miR-503-5p expression levels were 
associated with improved OS when assessed in both the skin and 
the serum. miR-503 has been shown to negatively regulate CD40 
gene expression when malignant human monocyte-derived cells 
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(U937 cells) were irradiated (31). The function of the CD40-CD40 
ligand (CD40L) pathway has been investigated in GvHD models 
(32). T and NK cells are activated when CD40 and CD40L ligate, 
which results in the release of established pro-inflammatory 
cytokines such as IFN-γ, IL-2, and IL-12 (33). Studies have shown 
that anti-CD40L antibodies can decrease GvHD severity (32). 
Activated CD4+ T-cells express CD40L that can be targeted by 
anti-CD40L antibodies. These antibodies block CD4+ T-cells, thus 
making them tolerant to host antigens, resulting in lower GvHD 
(34). Moreover, CD40 is also expressed in human keratinocytes in 
the skin (35). Since miR-503 and miR-424 are polycistronic, they 
have very similar seed sequences and have been shown to target 
the same genes and also be involved in monocyte to macrophage 
differentiation in an AML cell line study (36). In a GvHD-related 
study, investigators have shown that miR-424 levels are higher 
in cord blood CD4+ and CD8+ cells when compared to adult 
peripheral blood cells (37). It was also demonstrated that miR-
424 is overexpressed in adult blood CD14+ monocytes, when 
compared with CD4+ and CD8+ T-cells (37). It is known that 
during inflammation monocytes are recruited to the affected site 
and differentiate to either macrophages and/or DCs [as reviewed 
in Ref. (38)]. Therefore, miR-503-5p could be overexpressed to 
target CD40 gene expression and thus, inhibit T-cell activation. 
Its expression levels may also be upregulated as more monocytes 
are recruited and migrate from the blood to the host skin tissue.
Likewise, miR-365a-3p was under-expressed post-transplan-
tation. Xu et al. (39) have shown that miR-365a-3p is a negative 
regulator of IL-6, which is a cytokine involved in the control of 
immune responses (40). Studies have demonstrated that IL-6 
levels are elevated at the time of aGvHD onset in the sera of 
patients (41). Skin fibroblasts have also been shown to express 
IL-6 under inflammatory conditions (42). It may be possible that 
the decrease in miR-365a-3p expression post-transplant causes 
IL-6 level to increase in aGvHD patients.
miR-34a-5p was significantly differentially expressed between 
pre-transplant and skin stages 0–1 as well as stages 2–3 aGvHD 
biopsies. Similarly, it was differentially expressed between 
pre-transplant and grades 0–I and grades II–IV aGvHD when 
assessed according to overall clinical aGvHD. Expression was 
also significantly higher in D28 serum samples in patients who 
developed overall aGvHD or skin aGvHD. However, no signifi-
cant difference was observed between mild and moderate aGvHD 
in either the skin or the serum. Interestingly, miR-34a was not 
expressed at all when tested in a small cohort of scleroderma skin 
biopsies (n = 5, data not shown). Thus, the findings suggest that 
miR-34a-5p may be upregulated as a result of the allo-HSCT, as 
well as inflammation due to GvHD. miR-34a has previously been 
associated with aGvHD in Fanconi anemia (FA) (6). Patients with 
FA are particularly susceptible to developing high-grade aGvHD, 
thought to be mediated through impaired DNA repair processes 
leading to increased apoptosis (43). It was demonstrated that 
miR-34a expression was higher in aGvHD compared with no-
aGvHD, in both the skin and gut and that expression directly 
correlated with the number of apoptotic cells present in the gut 
(6). This supports the findings of this study in which miR-34a 
levels were elevated in aGvHD. Thus, serum miR-34a levels may 
be indicative of apoptosis occurring in target GvHD organs, thus 
serving as a potential serum biomarker of aGvHD. In allo-HSCT 
and GvHD, T-cell receptors (TCRs) are stimulated during the 
GvH cycle when T-cells recognize HLA mismatches between 
the patient and donor. This results in partial activation of the 
T-cells (44). Recently, it has been shown that overexpression of 
miR-34a is related to higher TCR T-cell activation. The positive 
correlation between miR-34a expression and TCR stimulation 
has been linked to diacylglycerol kinase-zeta (DAGK-ζ), which 
is an enzyme responsible for metabolizing diacylglycerol (DAG) 
(45). Lower DAGK-ζ results in higher T-cell activation as the cells 
become sensitive to TCR triggers, and miR-34a directly targets 
DAGK-ζ mRNA, leading to more un-metabolized DAG, which 
stimulates TCRs and enhanced T-cell activation (45).
In this study, low expression levels of miR-503-5p and miR-
34a-3p were indicative of improved OS. Interestingly, when 
considering skin histopathological aGvHD stage as the outcome, 
a significant statistical interaction was present between miR-
503-5p and miR-34a-3p and this was distinctly evident when 
survival status was added onto 3D plots for visualization. The 
biological mechanism underlying the statistical interaction needs 
further investigation, but our results are consistent with a “gate” 
mechanism, whereby at high levels of miR-34a-3p, miR-503-5p 
is the dominant effector and most patients have a lower chance 
of survival, while higher levels of miR-503-5p accompany more 
severe aGvHD. By contrast, as miR-34a-3p expression decreased, 
the effect of miR-503-5p was negligible, most patients survived, 
and the severity of aGvHD increased. It would be interesting to 
assess whether cutaneous microRNA expression patterns directly 
reflect aGvHD severity. However, patients who develop severe 
aGvHD are rare in the Newcastle Transplantation facility due to 
the controlled conditioning and prophylaxis treatments. Almost 
every patient in this center is administered with alemtuzumab 
(Campath). In this study, only one patient from the cutaneous 
cohort was diagnosed with skin aGvHD stage 3. Therefore, we 
could only analyze stage 2 and 1 versus pre-transplant biopsies. 
None of the microRNAs were associated with risk of relapse and 
it was not possible to perform competing risk analysis, due to the 
few cases present per group. It will therefore be important to vali-
date these results in larger, multi-center studies that incorporate a 
higher number of high stage 3-4 aGvHD patients. Furthermore, 
although it is encouraging that the potential biomarkers identi-
fied in this study can be confirmed in an independent cohort, 
additional expanded cohorts will allow for sub-stratification in 
order to investigate the impact of heterogeneous conditioning 
regimens and pre-transplant prophylaxis, as well as improve the 
strength of multivariate analyses.
In this study, whole skin biopsies were used for microRNA 
expression analysis. However, aGvHD mainly attacks the epider-
mal layer of the skin (2). Thus, the microRNA expression profiles 
observed are collective and may decrease the discriminatory 
specificity of the results. In addition, the proportion and types 
of cells in the epidermis and dermis are different. Thus, in order 
to fully understand the biology of the microRNAs, it may be 
essential to assess their expression levels separately in each layer 
of the skin, separated by laser capture microdissection.
The protein expression of microRNA targets was investigated 
in the same cohort. Results showed that c-Myc and p53-positive 
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cells were present in cutaneous biopsies of allo-HSCT patients. The 
proto-oncogene c-Myc is involved in fundamental processes such 
as differentiation, apoptosis, and cellular proliferation (46, 47). In 
this study, no significant association was determined between miR-
34a expression and c-Myc-positivity; however, significant positive 
correlation between p53-positive cells and miR-34a-5p expression 
was observed. This result is in support of the p53-positive feedback 
loop with miR-34a (12). p53-positive cells were observed even 
in pre-transplantation skin biopsies, and overall the number of 
p53-positive cells increased with aGvHD severity (p =  0.045). 
Taken together, these results may suggest that pre-transplant 
activation of p53 is due to the conditioning regimen, which is 
not sufficient to trigger miR-34a-5p overexpression. In the post 
allo-HSCT skin, p53 is overexpressed due to the conditioning regi-
men as well as the GvH reaction, which led to higher miR-34a-5p 
expression and therefore positive correlation in their expression.
In summary, this research has shown that miR-34a, miR-
503-5p, let-7c-5p, and miR-365a-3p may be implicated in both 
the transplant procedure and the pathogenesis of aGvHD. 
Expression of miR-503-5p, miR-34a-5p, and miR-34a-3p in 
serum demonstrated potential non-invasive biomarker potential. 
Further investigation into the experimentally validated targets of 
miR-34a, miR-503-5p, let-7c-5p, and miR-365a-3p may shed light 
on their impact at the protein level and their roles in maintaining 
skin homeostasis. These results need to be validated in a larger, 
multicentre cohort.
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